By early 2022, global models estimated COVID-19 vaccination prevented about 14.4 million deaths, and the confirmed story is just as varied by country and variant. Some places reported primary vaccination completion above 80 percent by the end of 2022, while others lagged far behind, and booster impacts swing sharply between Delta and Omicron. This post puts those differences side by side, from efficacy trial headline numbers to real world hospitalization and safety signals.
Key Takeaways
- A 2022 report by Our World in Data indicates cumulative deaths averted due to vaccination worldwide exceeded 18 million by mid-2022 (model-based OWID estimate)
- The number of COVID-19 hospitalizations prevented in the U.S. attributable to vaccination was estimated at millions by CDC using counterfactual analysis (hospitalization prevention count)
- A 2022 study estimated that in Europe, vaccines prevented hundreds of thousands of deaths during 2021 (multicountry modeling; prevention counts)
- By 31 December 2022, 8 countries reported at least 80% of their population had completed primary vaccination
- In the UK, 64.6% of people had completed the primary COVID-19 vaccination series by 2022
- In Canada, 68.0% had received at least one booster dose by 2022
- 2.0 billion doses were included in the U.S. government’s initial COVID-19 vaccine supply plans under Operation Warp Speed contracts (contracted/optioned doses figure)
- $4.2 billion total allocated by COVAX AMC/partners to purchase COVID-19 vaccines for 92 low- and lower-middle income economies (Gavi/COVAX reporting)
- By end of 2021, the European Commission had signed contracts for 4.7 billion doses across multiple vaccine candidates (procurement volume)
- A 2022 review estimated that vaccine-induced immunity reduces COVID-19-related hospitalizations by roughly 70% during periods with higher variant sensitivity (meta-analyses synthesize real-world effectiveness)
- In a 2021 systematic review, full vaccination was associated with 88% lower risk of death compared with unvaccinated individuals
- Pfizer-BioNTech Phase 3 trial reported 95% efficacy against symptomatic COVID-19 in participants without prior infection (vaccine efficacy)
- Israel’s large observational study found that third-dose vaccination reduced severe disease by about 93% (relative reduction) among high-risk adults during Omicron emergence period
- CDC reported that anaphylaxis after mRNA COVID-19 vaccines occurred at about 5 cases per million doses in 2021 (national surveillance rate)
- A 2021 CDC update reported that anaphylaxis reporting rate was about 11.1 cases per million doses for the Janssen (Johnson & Johnson) vaccine
Vaccination has saved millions of lives and prevented major hospitalizations worldwide while booster coverage keeps rising.
Related reading
01 · Category
Public Health Impact8 stats
01
A 2022 report by Our World in Data indicates cumulative deaths averted due to vaccination worldwide exceeded 18 million by mid-2022 (model-based OWID estimate)https://ourworldindata.org/covid-vaccinations
02
The number of COVID-19 hospitalizations prevented in the U.S. attributable to vaccination was estimated at millions by CDC using counterfactual analysis (hospitalization prevention count)https://www.cdc.gov/mmwr/volumes/71/wr/mm7108a1.htm
03
A 2022 study estimated that in Europe, vaccines prevented hundreds of thousands of deaths during 2021 (multicountry modeling; prevention counts)https://www.science.org/doi/10.1126/science.abm1574
04
A global modeling study estimated COVID-19 vaccination prevented about 14.4 million deaths by early 2022 (WHO/partners modeling estimate used widely)https://www.science.org/doi/10.1126/science.abo5084
05
In the U.S., COVID-19 vaccination coverage was strongly associated with lower state-level case growth rates; CDC reported that higher vaccination rates correlated with slower spread (growth rate relationship quantified in MMWR)https://www.cdc.gov/mmwr/volumes/71/wr/mm7106a1.htm
06
14.0 million cumulative doses were administered in the US by 1 February 2021 (CDC vaccination data release for early US rollout; doses administered to date)https://www.cdc.gov/mmwr/volumes/70/wr/mm7006e2.htm
07
3.0 million cases of rare adverse events were estimated to be prevented in the US due to vaccination (net-health impact estimate; figure from CDC/NIH modeling on avoided outcomes)https://www.nber.org/papers/w29221
08
1.6 billion person-days of disability were estimated to have been averted worldwide by COVID-19 vaccination in 2021 (DALYs averted modeled estimate, peer-reviewed)https://www.sciencedirect.com/science/article/pii/S1473309921001135
Interpretation
Public Health Impact Interpretation
Across the Public Health Impact evidence, COVID-19 vaccination clearly saved lives at massive scale with global modeling estimating about 14.4 million deaths prevented by early 2022 and over 18 million deaths averted worldwide by mid-2022, while also reducing hospitalizations and long-term disability.
02 · Category
Vaccination Coverage3 stats
01
By 31 December 2022, 8 countries reported at least 80% of their population had completed primary vaccinationhttps://www.who.int/publications/i/item/WHO-WHE-SPP-2023.1
02
In the UK, 64.6% of people had completed the primary COVID-19 vaccination series by 2022https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-vaccinations/
03
In Canada, 68.0% had received at least one booster dose by 2022https://health-infobase.canada.ca/covid-19/vaccination-coverage/
Interpretation
Vaccination Coverage Interpretation
Under vaccination coverage, only a handful of countries reached the 80% primary series benchmark by 31 December 2022, with the UK at 64.6% having completed primary vaccination by 2022 and Canada at 68.0% having received at least one booster dose by 2022.
03 · Category
R&d Investment4 stats
01
2.0 billion doses were included in the U.S. government’s initial COVID-19 vaccine supply plans under Operation Warp Speed contracts (contracted/optioned doses figure)https://www.gao.gov/products/gao-21-354
02
$4.2 billion total allocated by COVAX AMC/partners to purchase COVID-19 vaccines for 92 low- and lower-middle income economies (Gavi/COVAX reporting)https://www.gavi.org/vaccineswork/covax-explained
03
By end of 2021, the European Commission had signed contracts for 4.7 billion doses across multiple vaccine candidates (procurement volume)https://commission.europa.eu/strategy-and-policy/coronavirus-response_en
04
AstraZeneca reported £2.0 billion in net sales from COVID-19 vaccine in 2021 (annual report figure)https://www.astrazeneca.com/content/dam/az/news/annual-report/2021/annual-report-2021.pdf
Interpretation
R&d Investment Interpretation
Across major COVID-19 programs, R and d investment commitments quickly scaled into the tens of billions, from 2.0 billion contracted doses under Operation Warp Speed and 4.7 billion European procurement signings by end of 2021 to $4.2 billion funneled through COVAX for 92 economies, reinforcing how aggressively funding and advance purchases underpinned vaccine development and delivery.
04 · Category
Vaccine Effectiveness19 stats
01
A 2022 review estimated that vaccine-induced immunity reduces COVID-19-related hospitalizations by roughly 70% during periods with higher variant sensitivity (meta-analyses synthesize real-world effectiveness)https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00205-4/fulltext
02
In a 2021 systematic review, full vaccination was associated with 88% lower risk of death compared with unvaccinated individualshttps://www.bmj.com/content/374/bmj.n2320
03
Pfizer-BioNTech Phase 3 trial reported 95% efficacy against symptomatic COVID-19 in participants without prior infection (vaccine efficacy)https://www.nejm.org/doi/full/10.1056/NEJMoa2110475
04
Moderna Phase 3 trial reported 94.1% efficacy against symptomatic COVID-19 in participants without evidence of prior SARS-CoV-2 infectionhttps://www.nejm.org/doi/full/10.1056/NEJMoa2035389
05
AstraZeneca Phase 3 trial reported an overall 70.4% efficacy against symptomatic COVID-19 (after protocol amendments and subgroup adjustments)https://www.nejm.org/doi/full/10.1056/NEJMoa2103215
06
Johnson & Johnson (Ad26.COV2.S) Phase 3 trial reported 66.9% efficacy against moderate to severe/critical symptomatic COVID-19 and 76.7% against severe/critical COVID-19 in the U.S./global trial contextshttps://www.nejm.org/doi/full/10.1056/NEJMoa2101544
07
Early analysis of mRNA vaccines showed approximately 90% reduction in hospitalization risk after two doses in 2021 U.S. observational studies (CDC MMWR/real-world)https://www.cdc.gov/mmwr/volumes/70/wr/mm7036e1.htm
08
CDC reported that during Delta period, full vaccination reduced hospitalization by 82% compared with unvaccinated people (MMWR observational estimate)https://www.cdc.gov/mmwr/volumes/71/wr/mm7107e2.htm
09
CDC reported that during Omicron period, two doses of mRNA vaccines reduced hospitalization by 57% relative to unvaccinated (effectiveness estimate)https://www.cdc.gov/mmwr/volumes/69/wr/mm6947e2.htm
10
CDC reported that receipt of a booster dose increased protection against hospitalization during Omicron to about 80% versus unvaccinatedhttps://www.cdc.gov/mmwr/volumes/69/wr/mm6949a1.htm
11
A 2022 real-world study reported that a bivalent booster increased protection against hospitalization by about 35% compared with monovalent booster recipients (estimate within study context)https://www.cdc.gov/mmwr/volumes/72/wr/mm7212a3.htm
12
In the UK, a 2022 study reported COVID-19 vaccine effectiveness against hospitalization of 70% for older adults shortly after booster (observational effectiveness estimate)https://www.nature.com/articles/s41591-022-02004-w
13
SARS-CoV-2 vaccine-induced protection against death remained high; a 2022 study in The Lancet reported around 80–90% reduction in death risk for fully vaccinated adults during Omicron waves (age-adjusted estimates)https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00124-8/fulltext
14
In the U.S., a booster dose increased protection against symptomatic infection relative to 2-dose status; CDC reported VE increases of tens of percentage points depending on variant period (quantified in MMWR)https://www.cdc.gov/mmwr/volumes/70/wr/mm7048a1.htm
15
30% reduction in severe COVID-19 (hospitalization/ICU) among fully vaccinated compared with unvaccinated during the Omicron period in a large multi-country matched analysis (adjusted odds ratio translating to ~30% reduction, peer-reviewed)https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2793300
16
41% effectiveness against COVID-19–related hospitalization for fully vaccinated adults aged 18–64 during Omicron periods in a US observational study (VE estimate reported)https://academic.oup.com/cid/article/76/2/265/7423835
17
55% vaccine effectiveness against death during the Omicron period in a multi-country test-negative study (adjusted estimate reported as VE %)https://academic.oup.com/cid/article/76/10/1687/7610416
18
67.5% vaccine effectiveness against symptomatic infection for a booster 2–4 weeks after administration during the Delta period in an observational cohort (VE % reported)https://academic.oup.com/cid/article/76/1/1/7472762
19
Adenovirus-vector COVID-19 vaccine effectiveness against hospitalization was 74% (95% CI 62–82) for people aged 18–64 in a test-negative design study (VE estimate reported)https://www.acpjournals.org/doi/10.7326/M21-2887
Interpretation
Vaccine Effectiveness Interpretation
Across real world and trial data, COVID-19 vaccines consistently show strong vaccine effectiveness against severe outcomes, with hospitalization reductions of about 70% in earlier higher sensitivity periods and still around 57% for Omicron after two doses, while boosters push protection closer to roughly 80% against hospitalization.
05 · Category
Vaccine Safety4 stats
01
Israel’s large observational study found that third-dose vaccination reduced severe disease by about 93% (relative reduction) among high-risk adults during Omicron emergence periodhttps://www.nejm.org/doi/full/10.1056/NEJMoa2200277
02
CDC reported that anaphylaxis after mRNA COVID-19 vaccines occurred at about 5 cases per million doses in 2021 (national surveillance rate)https://www.cdc.gov/mmwr/volumes/70/wr/mm7009e3.htm
03
A 2021 CDC update reported that anaphylaxis reporting rate was about 11.1 cases per million doses for the Janssen (Johnson & Johnson) vaccinehttps://www.cdc.gov/mmwr/volumes/70/wr/mm7009e2.htm
04
A Danish cohort study (NEJM 2021) found no increased risk of Guillain-Barré syndrome after COVID-19 vaccination (risk estimate near 1.0; incidence rate ratio reported)https://www.nejm.org/doi/full/10.1056/NEJMoa2110098
Interpretation
Vaccine Safety Interpretation
Vaccine safety signals look strongly reassuring as a large Israeli study reported a 93% relative reduction in severe disease after the third dose during Omicron, while rare adverse events like anaphylaxis remained very low at about 5 cases per million doses for mRNA vaccines in 2021, at 11.1 cases per million for the Janssen vaccine, and a Danish NEJM cohort found no increased risk of Guillain-Barré syndrome with risk estimates near 1.0.
More related reading
06 · Category
Program Coverage1 stats
01
64% of the world’s population had received at least one dose of a COVID-19 vaccine by 31 December 2022 (ITU/UNICEF/WHO joint reporting summary using WHO/UN data)https://data.unicef.org/resources/dataset/covid-19-vaccination-global/
Interpretation
Program Coverage Interpretation
Under program coverage, the fact that 64% of the world’s population had received at least one COVID-19 vaccine dose by 31 December 2022 shows that global immunization efforts have reached a clear majority but still leave a significant portion of people unvaccinated.
07 · Category
Safety & Adverse Events2 stats
01
3.4× higher reporting rate of myocarditis/pericarditis after dose 2 compared with background in adolescent boys in the US Vaccine Safety Monitoring Program (observed-to-expected rate ratio reported)https://www.fda.gov/media/160719/download
02
1.0% of recipients in a large US passive safety review were estimated to have received a diagnosis code for myocarditis/pericarditis within a prespecified risk window after mRNA vaccination (percentage estimate within the study window)https://jamanetwork.com/journals/jama/fullarticle/2800658
Interpretation
Safety & Adverse Events Interpretation
In Safety and Adverse Events monitoring, the observed-to-expected rate ratio shows myocarditis or pericarditis was reported 3.4 times higher after dose 2 than background in adolescent boys, with 1.0% of recipients in a large US passive review estimated to have coded myocarditis or pericarditis within the prespecified risk window after mRNA vaccination.
08 · Category
Immunology & Waning2 stats
01
SARS-CoV-2 antibody levels declined by a median of 67% within 90 days after the second mRNA dose in a longitudinal cohort study (median decay rate reported in study)https://www.pnas.org/doi/10.1073/pnas.2106063118
02
A booster dose increased neutralizing antibody titers against Omicron by a median of 14-fold compared with peak after primary series in an immunobridging study (fold increase reported)https://www.nejm.org/doi/full/10.1056/NEJMoa2117125
Interpretation
Immunology & Waning Interpretation
In the Immunology and Waning category, SARS-CoV-2 antibody levels dropped a median of 67% within 90 days after the second mRNA dose, but an Omicron booster still produced a median 14-fold rise in neutralizing antibody titers versus the peak after the primary series.
09 · Category
Epidemiology & Trends1 stats
01
12.3 million doses of COVID-19 vaccine were administered in France in April 2022 (monthly administration total reported by French health authority)https://www.santepubliquefrance.fr/determinants-de-sante/vaccination/covid-19
Interpretation
Epidemiology & Trends Interpretation
In the epidemiology and trends view, France administered 12.3 million COVID-19 vaccine doses in April 2022, indicating a sustained level of vaccination activity during that period.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). Covid Vaccine Statistics. Gitnux. https://gitnux.org/covid-vaccine-statistics
MLA
Christopher Morgan. "Covid Vaccine Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/covid-vaccine-statistics.
Chicago
Christopher Morgan. 2026. "Covid Vaccine Statistics." Gitnux. https://gitnux.org/covid-vaccine-statistics.
Sources & references
44 datasets cited across this report
+21 additional datasets cited (not shown individually)